Pevonedistat

N/A

Report date: 2026/04/28 20:00:22
NMEFirst In Class

Base Information

Drug NamePevonedistat
Drug Alias Name培迪司他Pevonedistatum派伏司他TAK-924MLN-4924 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNEDD8 activating enzyme inhibitors
TargetsNEDD8 activating enzyme
Therapy Area/IndicationsChronic eosinophilic leukemia (CEL)Solid tumoursRichter's Syndrome +[42] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[25] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMillennium Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Southern CaliforniaLeipzig UniversityNational Cancer Institute +[7] 
Inactive CompaniesWashington University School Of MedicineUniversity Of Michigan Rogel Cancer CenterTakeda Pharmaceutical (China) Company Limited
Active IndicationsChronic eosinophilic leukemia (CEL)Solid tumoursRichter's Syndrome +[36] 
Inactive IndicationsHematologic NeoplasmsMesotheliomaMelanoma +[6] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG